Medtronic's most recent trend suggests a bearish bias. One trading opportunity on Medtronic is a Bear Call Spread using a strike $89.00 short call and a strike $94.00 long call offers a potential 10.62% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $89.00 by expiration. The full premium credit of $0.48 would be kept by the premium seller. The risk of $4.52 would be incurred if the stock rose above the $94.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Medtronic is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Medtronic is bearish.
The RSI indicator is at 34.73 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Medtronic Rises 3%
Fri, 04 Jan 2019 10:32:03 +0000
Investing.com – Medtronic (NYSE:MDT) rose by 3.03% to trade at $88.04 by 10:31 (15:31 GMT) on Friday on the NYSE exchange.
Celgene deal is a 'bold' move, says former Medtronic CEO
Thu, 03 Jan 2019 16:27:00 +0000
Former Medtronic CEO Bill George joins CNBC's "Squawk Alley" via phone to talk about the merger between Bristol-Myers and Celgene.
New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
Thu, 03 Jan 2019 14:01:00 +0000
January 3, 2019 – Medtronic plc (MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window. “Simply put, IQcast acts like a weather forecast for people with diabetes so they can better prepare for their day,” said Dr. Robert Vigersky, senior director, Medical & Clinical Affairs for Diabetes Group at Medtronic.
Medtronic Falls 3%
Wed, 02 Jan 2019 10:22:02 +0000
Investing.com – Medtronic (NYSE:MDT) fell by 3.14% to trade at $88.10 by 10:21 (15:21 GMT) on Wednesday on the NYSE exchange.
New Study Raises Concerns About Overuse of Stents
Mon, 31 Dec 2018 17:00:00 +0000
Stent manufacturers such as Abbott Laboratories and Medtronic still expect demand for stents to remain steady.
Also on Market Tamer…
Follow Us on Facebook